NSABP FOUNDATION, INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Employees: -

Market Cap: -

Website: http://www.foundation.nsabp.org

Clinical Trials

A Single Arm Phase II Study to Evaluate Treatment With Gevokizumab in Patients With Stage II/III Colon Cancer Who Are ctDNA-positive After Curative Surgery and Adjuvant Chemotherapy

Phase 2

Withdrawn

Conditions: Colon Cancer

Interventions: Drug: Gevokizumab
Diagnostic Test: Signatera test

First Posted Date: 2022-01-05

Last Posted Date: 2022-11-04

Lead Sponsor: NSABP Foundation Inc

Registration Number: NCT05178576

Locations: 🇺🇸
UF Health Davis Cancer Pavilion and Shands Med Plaza, Gainesville, Florida, United States
🇺🇸
University of Iowa, Iowa City, Iowa, United States
🇺🇸
Wake Forest Baptist Health, Winston-Salem, North Carolina, United States

and more 2 locations

Biological and Clinical Effects of Palbociclib With Ovarian Suppression and Letrozole in the Neoadjuvant Treatment of Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Drug: Letrozole
Drug: Palbociclib
Drug: Goserelin
Diagnostic Test: Oncotype DX Breast Recurrence Score

First Posted Date: 2018-08-14

Last Posted Date: 2022-04-20

Lead Sponsor: NSABP Foundation Inc

Target Recruit Count: 24

Registration Number: NCT03628066

Locations: 🇨🇦
Centre Hospitalier de l'Universite de Montreal, Montreal, Quebec, Canada
🇺🇸
Saddleback Memorial Medical Center, Laguna Hills, California, United States
🇺🇸
West Virginia University, Morgantown, West Virginia, United States

and more 12 locations

Study of Pembrolizumab With Pemetrexed and Oxaliplatin in Chemo-Refractory Metastatic Colorectal Cancer Patients

Phase 1

Conditions: Metastatic Colorectal Cancer

Interventions: Drug: Pembrolizumab
Drug: Pemetrexed
Drug: Dexamethasone
Drug: Oxaliplatin
Dietary Supplement: Folic Acid
Dietary Supplement: Vitamin B-12

First Posted Date: 2018-08-13

Last Posted Date: 2022-06-10

Lead Sponsor: NSABP Foundation Inc

Target Recruit Count: 33

Registration Number: NCT03626922

Locations: 🇺🇸
Cancer Care Specialists of Central Illinois, Decatur, Illinois, United States
🇺🇸
Decatur Memorial Hospital, Decatur, Illinois, United States
🇺🇸
Minnesota Oncology-Minneapolis, Minneapolis, Minnesota, United States

and more 12 locations

Study of Neratinib +Trastuzumab or Neratinib + Cetuximab in Patients With KRAS/NRAS/BRAF/PIK3CA Wild-Type Metastatic Colorectal Cancer by HER2 Status

Phase 2

Conditions: Metastatic Colorectal Cancer

Interventions: Drug: Trastuzumab
Drug: Cetuximab
Drug: Neratinib
Diagnostic Test: Guardant360 Diagnostic Test

First Posted Date: 2018-03-08

Last Posted Date: 2022-03-31

Lead Sponsor: NSABP Foundation Inc

Target Recruit Count: 35

Registration Number: NCT03457896

Locations: 🇺🇸
Kaiser Permanente-Anaheim, Anaheim, California, United States
🇺🇸
Kaiser Permanente-Zion, San Diego, California, United States
🇺🇸
Kaiser Permanente-San Francisco, San Francisco, California, United States

and more 44 locations

Study of Neoadjuvant Chemotherapy Plus Trastuzumab and Pertuzumab in HER2-Negative Breast Cancer Patients With Abnormal HER2 Signaling

Phase 2

Recruiting

Conditions: HER2-negative Breast Cancer

Interventions: Drug: Doxorubicin
Drug: Cyclophosphamide
Drug: Weekly Paclitaxel
Drug: Trastuzumab
Drug: Pertuzumab
Diagnostic Test: Celcuity CELx HSF

First Posted Date: 2018-01-26

Last Posted Date: 2023-03-06

Lead Sponsor: NSABP Foundation Inc

Target Recruit Count: 64

Registration Number: NCT03412643

Locations: 🇺🇸
Cancer Care Specialists of Central Illinois, Decatur, Illinois, United States
🇺🇸
Fort Wayne Medical Oncology and Hematology, Inc., Fort Wayne, Indiana, United States
🇺🇸
Greater Baltimore Medical Center, Baltimore, Maryland, United States

and more 40 locations

Clinical Trial of Neoadjuvant Chemotherapy With Atezolizumab or Placebo in Patients With Triple-Negative Breast Cancer Followed After Surgery by Atezolizumab or Placebo

Phase 3

Active, not recruiting

Conditions: Triple Negative Breast Cancer

Interventions: Drug: Placebo
Drug: Atezolizumab

First Posted Date: 2017-09-13

Last Posted Date: 2024-04-08

Lead Sponsor: NSABP Foundation Inc

Target Recruit Count: 1550

Registration Number: NCT03281954

Locations: 🇺🇸
Waverly Hematology Oncology, Cary, North Carolina, United States
🇺🇸
Aurora Cancer Care-Kenosha South, Kenosha, Wisconsin, United States
🇺🇸
Meritus Center for Clinical Research, Hagerstown, Maryland, United States

and more 206 locations

Study of Durvalumab (MEDI4736) After Chemo-Radiation for Microsatellite Stable Stage II-IV Rectal Cancer

Phase 2

Completed

Conditions: Rectal Cancer

Interventions: Drug: durvalumab

First Posted Date: 2017-04-05

Last Posted Date: 2022-04-20

Lead Sponsor: NSABP Foundation Inc

Target Recruit Count: 45

Registration Number: NCT03102047

Locations: 🇺🇸
Smilow Cancer Hospital Care Center at Trumbull, Trumbull, Connecticut, United States
🇺🇸
Strecker Cancer Center, Belpre, Ohio, United States
🇺🇸
Cancer Care Specialists of Central Illinois, Decatur, Illinois, United States

and more 40 locations

Study of Durvalumab and Tremelimumab After Radiation for Microsatellite Stable Metastatic Colorectal Cancer Progressing on Chemotherapy

Phase 2

Completed

Conditions: Colorectal Cancer Metastatic

Interventions: Drug: durvalumab
Drug: Tremelimumab

First Posted Date: 2017-01-02

Last Posted Date: 2022-12-05

Lead Sponsor: NSABP Foundation Inc

Target Recruit Count: 33

Registration Number: NCT03007407

Locations: 🇺🇸
St. Joseph Mercy-Canton, Canton, Michigan, United States
🇺🇸
Centralia Oncology Clinic, Centralia, Illinois, United States
🇺🇸
UF Health Davis Cancer Pavilion and Shands Med Plaza, Gainesville, Florida, United States

and more 15 locations

A Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients With Colon Cancer

Phase 3

Terminated

Conditions: Stage III (IIIB or IIIC) Colon Cancer

Interventions: Drug: Placebo
Drug: Regorafenib

First Posted Date: 2016-01-26

Last Posted Date: 2022-04-14

Lead Sponsor: NSABP Foundation Inc

Target Recruit Count: 34

Registration Number: NCT02664077

Locations: 🇺🇸
McLeod Cancer Center for Treatment and Research, Florence, South Carolina, United States
🇺🇸
Thompson Cancer Survival Center, Knoxville, Tennessee, United States
🇺🇸
First Health of the Carolinas Cancer Center, Pinehurst, North Carolina, United States

and more 48 locations

A Phase II Randomized Study Evaluating the Biological and Clinical Effects of the Combination of Palbociclib With Letrozole as Neoadjuvant Therapy in Post-Menopausal Women With Estrogen-Receptor Positive Primary Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer
Breast Carcinoma
Breast Tumors

Interventions: Drug: Letrozole
Drug: palbociclib

First Posted Date: 2014-11-20

Last Posted Date: 2022-01-13

Lead Sponsor: NSABP Foundation Inc

Target Recruit Count: 307

Registration Number: NCT02296801

Locations: 🇺🇸
Metro-Minnesota CCOP, Saint Louis Park, Minnesota, United States
🇺🇸
Hope Women's Cancer Centers, Asheville, North Carolina, United States
🇺🇸
University of Pittsburgh, Pittsburgh, Pennsylvania, United States

and more 48 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy